REPLIMUNE GROUP, INC. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
REPLIMUNE GROUP, INC. (REPL) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $4.87 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-06-29.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-06-29
- REPLIMUNE GROUP, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2026 was $4.87M, a 429.21% increase from fiscal 2025.
- REPLIMUNE GROUP, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $921.00K.
- REPLIMUNE GROUP, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $0.00.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month |
|---|---|
| 2026-03-31 | $4.87M 10-K · filed 2026-06-29 |
| 2025-03-31 | $921.00K 10-K · filed 2026-06-29 |
| 2024-03-31 | $0.00 10-K · filed 2025-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |